Related Experiment Videos
Oxandrolone in AIDS-wasting myopathy
1Department of Neurology, University of Miami School of Medicine, Florida, USA.
AIDS (London, England)
|December 1, 1996
Summary
Oxandrolone treatment improved weight and well-being in HIV-positive men with wasting syndrome. Higher doses may warrant further study, as muscle strength did not significantly improve at the doses used.
Area of Science:
- Endocrinology
- Infectious Diseases
- Clinical Pharmacology
Background:
- AIDS-associated wasting and myopathy significantly impact patient health.
- Anabolic-androgenic steroids are being investigated for managing these conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of oxandrolone for treating AIDS-associated myopathy and wasting.
Main Methods:
- A multicenter, double-blind, placebo-controlled study.
- 63 HIV-seropositive men with significant weight loss were randomized.
- Treatment groups received placebo, 5 mg/day, or 15 mg/day oxandrolone for 16 weeks.
Main Results:
- Oxandrolone treatment led to weight gain or maintenance compared to placebo-induced weight loss.
- The 15 mg/day group reported increased appetite and activity.
- No significant dose-related adverse events or laboratory abnormalities were observed.
Conclusions:
- Oxandrolone (5-15 mg/day) positively impacted weight and well-being in HIV-associated wasting.
- Muscle strength did not improve significantly at tested doses.
- Oxandrolone was well-tolerated, suggesting further research with higher doses is warranted.